TABLE 2.

In vitro antifungal activities of antifungal drug controlsa

Species and strain or isolateIC50/MIC/MFC (μM) of:b
AMBFLUKTCCASPOUDATRB
C. albicans
    ATCC 140530.3/1.0/1.40.5/1.3/−0.01/0.02/−0.05/0.10/0.26>542.7c/−/−13.7/−/−
    ATCC 601930.2/1.0/1.40.4/0.6/−0.01/0.02/−0.03/0.10/0.52>542.7/−/−5.3/−/−
    ATCC 323540.3/1.0/1.40.8/5.7/−0.01/0.03/−0.07/0.13/1.03>542.7/−/−2.6/−/−
    ATCC 900280.3/1.0/1.40.8/6.4/−<0.01/0.01/−0.06/0.19/0.26−/−/−10.8/−/−
    ATCC 2009550.6/2.7/2.70.4/1.3/−<0.01/0.01/−0.05/0.13/0.13>542.7/−/−3.1/51.5/−
    Isolate 1d0.2/1.0/1.40.8/5.1/−<0.01/0.10/−0.05/0.10/0.26>542.7/−/−11.2/−/−
    Isolate 17d0.2/1.0/1.4163.3/−/−0.3/−/−0.04/0.13/0.26>542.7/−/−>68.3/−/−
Other Candida spp.
    C. glabrata ATCC 900300.4/1.4/1.429.5/81.6/−0.7/4.7/-0.05/0.13/0.26−/−/−−/−/−
    C. krusei ATCC 62580.7/2.0/2.7125.7/163.3/−0.4/1.1/−0.1/0.4/1.0>542.7/−/−>68.3/−/−
    C. parapsilosis ATCC 220190.3/2.0/5.43.4/10.2/−0.04/0.13/−0.2/0.5/−>542.7/−/−0.4/42.9/−
    C. tropicalis ATCC 7500.3/1.0/1.44.3/15.3/−0.04/0.19/−0.06/0.10/0.26>542.7/−/−45.4/−/−
C. neoformans e
    ATCC 901130.3/0.7/0.78.5/20.4/163.30.1/0.3/1.20.4/1.0/2.125.3/271.3/542.70.5/1.1/1.1
    ATCC 660310.08/0.34/0.340.7/5.1/20.40.02/0.15/0.590.1/0.5/1.02.7/135.7/271.30.4/4.3/8.6
Aspergillus spp.
    A. fumigatus ATCC 2043051.2/2.0/10.8−/−/−2.7/4.7/−?f/−/−−/−/−1.1/4.3/−
    A. fumigatus ATCC 909060.9/1.4/2.7−/−/−3.2/7.1/−0.2/16.5/−−/−/−1.0/4.3/−
    A. flavus ATCC 2043041.5/2.7/−−/−/−2.8/4.7/−?f/−/−−/−/−0.3/2.1/8.6
    A. niger ATCC 164040.9/2.0/−−/−/−6.0/9.4/−−/−/−414.9/−/−0.7/2.1/−
Trichophyton spp.
    T. mentagrophytes ATCC MYA-44390.9/1.4/1.424.2/81.6/−0.1/0.7/−0.2/−/−378.9/542.7/−<0.02/0.17/0.27
    T. mentagrophytes ATCC 95330.6/2.0/2.729.5/61.2/−0.2/0.4/−0.3/−/−279.0/542.7/−<0.02/0.05/0.27
    T. rubrum ATCC MYA-44380.6/1.4/5.42.7/6.4/−0.01/0.08/−0.06/0.10/−111.3/542.7/−4.2/21.4/−
    T. rubrum ATCC 102180.6/1.4/1.41.8/1.9/163.30.02/0.04/−−/−/−270.0/542.7/−<0.02/0.10/0.13
  • a The highest test concentrations of AMB, FLU, KTC, CASPO, UDA, and TRB were 10.8, 163.3, 9.4, 16.5, 542.7, and 68.3 μM, respectively.

  • b Values are means from two independent experiments, each with two replicates; the run-to-run variability was within one- or twofold. −, not active at the highest test concentration.

  • c Some growth inhibition (25 to 49% inhibition) was found at that concentration.

  • d Patient isolates were obtained during fluconazole therapy; isolate 1 (first isolate) and isolate 17 (last isolate) were azole resistant (35).

  • e Values are means from one experiment with two replicates.

  • f XLFit could not calculate an IC50, as growth was present at high and low test concentrations but inhibition was observed at mid-concentrations, possibly due to a concentration effect.